This company listing is no longer active
2965 Stock Overview
Engages in the investment, research and development, manufacturing, sales, and distribution of pharmaceutical products in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
China NT Pharma Group Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.30 |
| 52 Week High | HK$0.38 |
| 52 Week Low | HK$0.24 |
| Beta | -1.26 |
| 11 Month Change | -17.81% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -10.45% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| 2965 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 17.6% | 9.4% | 8.7% |
| 1Y | n/a | 30.8% | 25.5% |
Return vs Industry: Insufficient data to determine how 2965 performed against the Hong Kong Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 2965 performed against the Hong Kong Market.
Price Volatility
| 2965 volatility | |
|---|---|
| 2965 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 7.6% |
| 10% most volatile stocks in HK Market | 16.6% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 2965 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2965's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 16 | David Ng | www.ntpharma.com |
China NT Pharma Group Company Limited, together with its subsidiaries, engages in the investment, research and development, manufacturing, sales, and distribution of pharmaceutical products in the People’s Republic of China. It manufactures, sells, and trades in prescription medicines; offers products in the tumor and blood system diseases, digestive system diseases, central nervous system diseases, diseases of respiratory system, and other therapeutic fields; and produces and sells NT branded products. The company also provides marketing and promotion services to suppliers, and logistics and consulting services.
China NT Pharma Group Company Limited Fundamentals Summary
| 2965 fundamental statistics | |
|---|---|
| Market cap | HK$68.66m |
| Earnings (TTM) | -HK$36.44m |
| Revenue (TTM) | HK$8.02m |
9.2x
P/S Ratio-2.0x
P/E RatioIs 2965 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2965 income statement (TTM) | |
|---|---|
| Revenue | CN¥7.37m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥7.37m |
| Other Expenses | CN¥40.86m |
| Earnings | -CN¥33.49m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | -454.67% |
| Debt/Equity Ratio | -101.3% |
How did 2965 perform over the long term?
See historical performance and comparison